ADX71149 Phase 2 epilepsy clinical study’s independent interim review committee (“IRC”) recommends continuing study CHF 5.6M ($ 6.1M) of cash and cash equivalents at March 31, 2023 Ad Hoc Announcement …
Read Full Story at source (may require registration)
SINGAPORE, Jan. 23, 2025 (GLOBE NEWSWIRE) -- RF Acquisition Corp. (Nasdaq: RFAC) (“RFAC”), a publicly traded special purpose acquisition company,...
TORONTO, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Lumine Group Inc. (“Lumine Group” or “the Company”) (TSXV: LMN), a global buy-and-hold forever...
– NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES –Fredericton, New Brunswick, Jan. 23, 2025 (GLOBE...
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers...
PRINCETON, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Clearway Energy, Inc. (NYSE: CWEN, CWEN.A) plans to report Fourth Quarter 2024...
DALLAS, Jan. 23, 2025 (GLOBE NEWSWIRE) -- — Dorchester Minerals, L.P. (NASDAQ:DMLP) announced today the Partnership’s fourth quarter 2024 cash...
